October 15, 2010 13:25 ET

bioRASI to Sponsor the 2010 GPhA Fall Technical Conference in North Bethesda, Maryland

The Leading ANDA and 505(b)(2) CRO to Showcase New White Paper Series

HOLLYWOOD, FL--(Marketwire - October 15, 2010) -  bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will participate as a premier sponsor of the 2010 GPhA Fall Technical Conference in North Bethesda, Maryland, on October 19 - 21st. bioRASI will be exhibiting at booth #6 and will showcase its strategies and solutions to overcome the challenges within ANDA and 505(b)(2) clinical endpoint studies.

In addition, bioRASI will be introducing the first in a series of White Papers highlighting clinical endpoint ANDA Program Optimization techniques for the generics and specialty pharmaceutical industry. 

"bioRASI has emerged as the leader in conducting clinical endpoint ANDA and 505(b)(2) studies," said Dr. Boris Reznik, Chairman of bioRASI. "Every CE ANDA program we undertake provides us with new insights into varying aspects of these complex types of clinical trials. As we analyze the specific issues and questions raised by these studies in an attempt to develop solutions, we continuously improve our overall ability to not only optimally resolve a single issue, but also to optimize the overall process."

"We owe our knowledge and ability to optimize CE ANDA programs to our sponsors and to the generics drug industry as a whole. It is only natural to share some of the knowledge we have gained as well as the approaches we have developed with the industry itself," Dr. Reznik continued.

bioRASI will be publishing the white papers several times a year, addressing and analyzing different aspects of optimization, and making them available on their website, at marketing and technical conferences and through other established electronic publishing services.

About bioRASI

bioRASI is a Full Service Global CRO uniquely focused on clinical endpoint ANDA and 505(b)(2) programs. This experience and expertise allow bioRASI to facilitate obtaining FDA approvals by delivering high quality regulatory and clinical strategies, solutions and services, while saving their clients critical time. bioRASI's services include program optimization, project management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI leverages its unique access to the world's largest facilities and patient populations in the U.S., Europe and Asia to achieve unparalleled scientific, clinical and business results at significantly lower costs. bioRASI is headquartered in Hollywood, FL and has regional offices across in the U.S and overseas.

Contact Information